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Abstract: This systematic review aims to analyze the effect of the local application of statins
in the regeneration of non-periodontal bone defects. A systematic study was conducted with
the Pubmed/Medline, Embase, Cochrane Library and Scielo databases for in vivo animal studies
published up to and including February 2019. Fifteen articles were included in the analysis. The
local application of the drug increased the percentage of new bone formation, bone density, bone
healing, bone morphogenetic protein 2, vascular endothelial growth factor, progenitor endothelial
cells and osteocalcin. Meta-analyses showed a statistically significant increase in the percentage of
new bone formation when animals were treated with local statins, in contrast to the no introduction
of filling material or the introduction of polylactic acid, both in an early (4–6 weeks) and in a late
period (12 weeks) (mean difference 39.5%, 95% confidence interval: 22.2–56.9, p <0.001; and mean
difference 43.3%, 95% confidence interval: 33.6–52.9, p < 0.001, respectively). Basing on the animal
model, the local application of statins promotes the healing of critical bone size defects due to its
apparent osteogenic and angiogenic effects. However, given the few studies and their heterogenicity,
the results should be taken cautiously, and further pilot studies are necessary, with radiological and
histological evaluations to translate these results to humans and establish statins’ effect.
Keywords: statins; bone formation; bone regeneration; HMG-CoA reductase inhibitors
1. Introduction
Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, are widely
used agents for lowering cholesterol concentrations. These drugs reduce the progression and may
induce the regression of atherosclerosis and are associated with a reduction in cardiovascular morbidity
and mortality [1–7].
Although this is their main application, because mevalonate, the product of HMG-CoA
reductase’s reaction, is the precursor of many other non-steroidal isoprenoid compounds other than
cholesterol; their inhibiting role has pleiotropic effects [1,3,5–7]. Those include the anti-inflammatory,
immunomodulatory and antimicrobial properties [3,4]. Statins have also been shown to interfere in
the process of bone turnover and regeneration due to their action on different types of cells, including
osteoblasts, osteoclasts, endothelial cells and mesenchymal stem cells [2–7]. For this reason, they have
been studied for the treatment of osteoporosis without finding clear conclusions [3,5,6]. The potential
benefit of these drugs in bone regeneration has recently been studied [2,3,5,7].
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Two key points in the development of new applications of statins are its low cost and its relatively
good safety profile [1,5]. Side effects are rare but can be serious, especially liver toxicity, myositis
and rhabdomyolysis [1,3,4]. This is one of the reasons why the interest in investigating local delivery
strategies is growing [3,7]. Secondly, with oral treatment, much of the drug may be lost during first pass
of metabolism, so that higher doses will be needed to be effective in the defect site [3,7]. In addition,
local application will facilitate the management of the concentration necessary to take advantage of the
antimicrobial effect of statins [3].
Studies analyzing the effect of statins on the regeneration of non-periodontal bone defects are still
mostly in the preclinical phase, and evaluate radiological, histological and analytical parameters to
assess their impact [8–22].
In this context, the present systematic review is based on the PICO question. P: animals with
induced bone defects; I: local application of statins; C: compared with no treatment or placebo; O:
improvement in bone healing.
2. Material and Methods
An electronic search was conducted in the Pubmed, Cochrane and Scielo databases in February
2019. No limitations were established regarding the publication date. The following key terms were
applied: “Statins” or “HMG-CoA reductase inhibitors;” or “Lipid-lowering medications” and “Bone
formation,” or “Bone regeneration,” or “Bone healing,” or “Bone turnover” or “Bone metabolism”.
The titles and abstracts of all the articles located were read to select in vivo studies in animal
models analyzing the effect of a local application of statins on bone defects’ regenerations. Works not
written in English or Spanish, and reviews and in vitro experimental studies, were excluded. Those
in vivo studies that evaluated the effect of statins on implant osseointegration, or as an adjunct to
periodontal treatment, and those in which statins were administered systemically, were also discarded.
The full text of the selected studies was then evaluated. Articles in which the sample presented
induced osteoporosis; a bone defect was not created; the defect was filled with bone graft or bone
substitutes, such as tricalcium phosphate; and when the application of statins was not within the defect,
were excluded too. A follow-up of less than 4 weeks or a sample of less than 15 were also used as
exclusion criteria.
Due to the little existent literature on the subject, the animal species, the type and dose of statin
administered and the rest of the substances that made up the solution or implant introduced in the
defect, were not considered.
The qualities and risks of bias of the animal studies were assessed using the ARRIVE (Animal
Research: Reporting in vivo Experiments) guidelines [23] and the SYRCLE’s (Systematic Review Centre
for Laboratory Animal Experimentation) tool (First version, Central Animal Laboratory, Radboud
University Medical Center, Nijmegen, the Netherlands) [24], developed from the Risk of Bias tool of
the Cochrane Collaboration. The review itself was assessed using the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) scale of Moher et al, 2009 [25], with 22 items.
Pooled estimates from the studies were analyzed using a continuous random-effects model
meta-analysis. The evaluated variable was changes produced as a percentage of new bone under the
following intervention: the local application of simvastatin in the created defect versus no introduction
of filling material or introduction of placebo.
Forest plots were produced to graphically represent the differences in outcomes of the percentages
of new bone values; p < 0.001 was used as the level of significance. Heterogeneity was assessed with
an de x2 test and a I2 test. The OpenMeta [analyst] tool (First version, Brown University, Providence,
RI, USA) was employed in the statistical analysis.
3. Results
Of the 192 articles initially located in the electronic search, 14 were discarded due to duplication.
After reading titles and abstracts, 155 were excluded, as they did not fulfill the selection criteria. The
Materials 2019, 12, 2992 3 of 12
full texts of the 23 remaining articles were read, discarding two in which osteoporosis was induced to
animals; one as no bone defect was created; another in which statins were administered transdermally;
two as the statins’ matrix was bone graft; one in which the drug was introduced at the same time as
tricalcium phosphate; and another one because filling material was injected near the defect, but not
inside it.
Following the selection process, this review analyzed a total of 15 in vivo animal studies evaluating
the effect of local application of statins in the regeneration of induced bone defects (Figures 1–3) (Table 1).
The total animal population was 546 (18 dogs, 36 rabbits and 492 rats), distributed between 287 as
controls and 315 in intervention groups, 56 of them being in both groups at the same time with different
bone defects treated with different filling material [15,16,22].
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Table 1. Summary of the animal studies reviewed.
Animal







200 mg polylatcic acid (1a)// 200 mg polylatcic acid + 50 mg
simvastatin (2a) (rabbit) // 20 mg polylactic acid (1b)// 20
mg polylactic acid + 5 mg simvastatin (2b) (rat)
42 and 72
days
New bone formation, BMP-2,
HIF-1α, GFP-labeled BMSCs,
EPCs and BMSCs
Bone formation, EPCs periphereal blood,






No filling material (1)// collagen sponges soaked in water
(2)// collagen sponges + 2.2 mg/50 µL simvastatin (3)//
collagen sponges + 0.5 mg/50 µL simvastatin (4)
30 and 60





No filling material (1)// 6 mg PRF(2)// 1mg simvastatina +





VEGF; OPG, RANKL, ALP,
OSC and BMD
Bone formation in groups 2, 3 and 4;
bone maduration in group 4 at 60 days;
BMP-2 and VEGF in groups 2, 3 and 4;
OPG, OSC and ALP in groups 3 and 4;
RANKL in groups 3 and 4; BMD in
group 4; complete bone healing at 60





25% polyethylene glycol 400 + 75% hyaluronic acid (1)//




Radiographic bone union, time
bone healing,
histomorphometry






No filling material (1)// no filling material +
poly(lactic-co-glycolic acid) membrane (2)// 5 mg
simvastatin + poly(lactic-co-glycolic acid) microspheres +
poly(lactic-co-glycolic acid) membrane (3)//
poly(lactic-co-glycolic acid) microspheres +
poly(lactic-co-glycolic acid) membrane (4)
30 and 60
days
New bone formation, OPN,
BSP, OSAD, histomorphometry






250 mg simvastatin conjugated with gelatin hydrogel (1)//
gelatin hydrogel alone (2)




analysis, capillary density and
OB density, blood perfusion,
biomechanical analysis (stress,
extrinsic stiffness, failure








50 µL PBS (1)// 50 µL biodegradable polymer nanoparticle
(2)// 50 µL biodegradable polymer nanoparticle delivering
0.2 µg/day lovastatin (3)// 50 µL biodegradable polymer
nanoparticle delivering 1µg/day lovastatin (4)// 50 µL
biodegradable polymer nanoparticle delivering 1.5 µg/day
lovastatin(5)// 50 µL biodegradable polymer nanoparticle






Bone healing, cortical fracture gap at 4
weeks, maximum force to fracture and
work-to-fracture (groups 4 and 5),
lovastatin undetectable at 28 days
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Table 1. Cont.
Animal





3:1 chitosan to Carbapol® + 2% Imwitor® + 19.88-24.38 mg
rosuvastatin sponges (1)// no filling material (2)





2.5 mg/mL simvastatin in 0.2 ml water + hydrogel (1)// 2.5
mg/mL simvastatin in 0.2 ml water + atelocollagen sponge
(2)// hydrogel (3)// atelocollagen sponge (4)// no filling
material (5)
7, 14, 28, 56
and 84 days
New bone area ratio, BMP-2,
histomorphometry
Number cells stained positive to BMP-2
at 14 and 28 days (groups 1 and 2), new
bone area ratio at 14, 28, 56 and 84 days





Slow-release degradable hydroxypropyl methylcellulose
(70% simvastatin and 30% Methocel K100M) (1)//
Slow-release degradable hydroxypropyl methylcellulose




OV/BV, Os.Th, MS/BS, MAR,
BFR/BS, double-labeled calcein
surface





Polyethylene glycol in PBS (200 µL) (1a)// Polyethylene
glycol in PBS (200 µL) + 25 µg LV-MPs (2a)// Polyethylene
glycol in PBS (200 µL) + 100 µg LV-MPs (3a)// Polyethylene
glycol in PBS (200 µL) at 14, 28 and 42 days (1b)//
Polyethylene glycol in PBS (200 µL) + 100 µg LV-MPs at 14,
28 and 42 days (2b)
28 days/ 14,
28, 42 and 56
days
Mineralized bone formation,
bone volume, density in the
defects, newly formed bone
matrix
Volume and density of newly formed
bone (3a)// Volume and density of newly




Randomized PBS (1)// 0.5 mL PRP (2)// 0.1 mL simvastatin (3)
56 and 112
days
New bone forming area,
fibroblasts, osteoblasts,
osteoclasts, vessel diameter
New bone forming area, fibroblasts,






PLGA-PEG-PLGA (1)// SIM/PLGA-PEG-PLGA(2)// no
filling material(3) 28 days
New bone formation ratio,





Collagen sponge (1,2) // Collagen sponge with saline
solution containing 1 mg rosuvastatin (3,4)
14 and 28





1 mg PLGA nanoparticles containing lovastatin (1a) //
gelfoam (1b) // 3 mg nanoparticles containing lovastatin
(2a) // gelfoam (2b) // 1 mg nanoparticles containing
lovastatin (3a) // 1 mg nanoparticles without lovastatin (3b)
// 3 mg nanoparticles containing lovastatin (4a) // 3 mg
nanoparticles without lovastatin (4b)
21, 42, 63
and 84 days
Volume changes of the defect,
histomorphometry
Remaining bony defect in volumen (1a)
at 42, 63 and 84 days
Abbreviations: ALP: alkaline phosphatase enzyme, BFR/BS: bone formation rate, BMD: bone mineral density, BMP-2: bone morphogenetic protein-2, BMSC: bone marrow-derived
mesenchymal stem cell, BSP: bone sialoprotein, EPC: endothelial progenitor cell, GFP: green fluorescent protein, HIF-1α: hypoxia-inducible transcription factor 1-alpha, LV-MP:
injectable lovastatin microparticles, MAR: mineral apposition rate, MBV/TV: mineralized bone volume, MS/BS: mineralized surface, NE: not specified, OB: osteoblasts, Ob.S/BS:
osteoblast surface, OPG: osteoprotegerin, OPN: osteopontin, OSAD: osteoadherin, OS/BS: osteoid surface, OSC: osteocalcin, Os/Th: osteoid thickness, OV/BV: osteoid volume, PBS:
phosphate-buffered saline, PLGA: poly(lactic-co-glycolic acid), PLGA-PEG-PLGA: poly (D,L-lactide-co-glycolide)-poly(ethylene glycol)-poly (D,L-lac-tide-co-glycolide), PRF: platelets rich
fibrin, PRP: platelet-rich plasma, RANKL: receptor activator of nuclear factor kappa-B ligand, RR: relative ratio, RT-PCR: real time polymerase chain reaction, SIM/PLGA-PEG-PLGA:
simvastatin/poly(D,L-lactide-co-glycolide)-poly(ethylene glycol)-poly (D,L-lac-tide-co-glycolide), VEGF: vascular endothelial growth factor.
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These articles compare the non-introduction of filling material [9,10,12,15,16,20], and the
introduction of phosphate-buffered saline [14–19], polylactic acid [8,12], collagen sponges [9,16,21],
hyaluronic acid [11], polyethylene glycol [11,18], gelatin hydrogel [13,16,22] or hydroxypropyl
methylcellulose [17], with the introduction into the defect area of preparations containing statins [8,22].
The statin used and the dose were different depending on the study, with simvastatin being the
most employed [8–10,12,13,16,17,19,20], followed by lovastatin [11,14,18,22]. Rosuvastatin [15,21] was
used in only two of the articles.
In all the works [8–22], the filling material was introduced at the time of the bone defect creation,
except for one, in which a parallel experiment was carried out, in which the injections were made at
the time of surgery, and at 14, 28 and 42 days [18].
The samples were followed for a variable period of time, between 28 and 112 days, with the mean
of the studies being 58.9 days. During this time, between one and five analyzes were performed, with
two analyzes being the most frequent [8,22].
The studied parameters can be grouped into radiological, histological and analytical, highlighting
the amount of new bone [8–10,16,18–21], bone density [9,10,13,18], bone healing [11–15] and bone
morphogenetic protein 2 (BMP-2) [8,10,13,16] as the most studied parameters.
In all the trials in which the percentage of new bone formation was analyzed, statistically significant
results were obtained when comparing the groups in which the filling material contained statins
with the control group [8,10,16,18]. Only in two of them did the necessary data appear in order to
compare them quantitatively [8,16]. Three other studies measured the reossification area [9,19,21],
with statistically significant results in two of them [19,21]. In the only work in which the ratio of new
bone formation was analyzed, the results were statistically significant [20].
Three [10,13,18] of the four studies [9,10,13,18] that analyzed bone density in the defect area
showed significant results two months after local application of statins. Bone healing was statistically
better in the intervention groups in the five trials in which it was analyzed, considerably reducing the
healing periods compared to controls [11–15].
In relation to BMP-2, all the studies that analyzed it found a higher expression or a greater number
of cells that stained positive for BMP-2 after the application of statins [8,10,13,16].
The vascular endothelial growth factor (VEGF) was significantly increased after the local treatment
in the two cases in which it was analyzed [10,13].
The two trials that evaluated progenitor endothelial cells (EPCs), either in the peripheral blood [8]
or in the perilesional tissue [13], obtained a statistically significant increase in the values after the local
application of statins.
In three studies, osteoblast levels were analyzed. In one, density was evaluated [13], obtaining
a significant increase in the intervention group; in another, the percentage of surface covered with
osteoblasts was measured [17], without finding significant differences between both groups. In the last
one, the number of osteoblasts in a given area was counted, obtaining a significantly higher value in
the intervention group [19].
As for osteocalcin, a significant increase in its expression was also observed after the use of statins
in the two trials where it was studied [10,13].
The biomechanical parameters were analyzed twice, obtaining a significant difference of the
maximum strength and work to fracture between the intervention group and the control group in one
of the studies [14], and of the relative ultimate stress and the relative extrinsic stiffness in the other [13].
Some parameters were only measured in one of the articles analyzed, obtaining in some cases,
statistically significant differences with respect to the control group: bone marrow-derived mesenchymal
stem cells (BMSCs) [8], hypoxia-inducible factor 1-alpha (HIF- 1α) [8], osteoprotegerin [10], alkaline
phosphatase enzyme [10], receptor activator for nuclear factor κ B ligand (RANKL) [10], width
of trabecula [13], capillary density [13], mRNA expression of the angiogenic markers endothelial
nitric oxide synthase (eNOS) and stromal cell-derived factor 1 (SDF-1) [13], osteoid volume [17],
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osteoid thickness [17], double-labeled calcein surface [17], fibroblasts [19], osteoclasts [19] and vessel
diameter [19].
Separate meta-analyses were performed to analyze the mean differences of percentages of new
bone formed between studies [8,16]. Those two trials evaluated the values of that parameter at different
points in time (4–6 and 12 weeks) after the application of local simvastatin in the intervention group
(n = 26) versus no introduction of filling material or introduction of polylactic acid in the control group
(n = 26).
The forest plot (Figure 4) shows a percentage of new bone mean difference of 39.5% with a p-value
< 0.001 (95% CI: 22.2 to 56.9, heterogeneity I2 = 98.4%, P < 0.001) at 4–6 weeks after the intervention.
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The forest plot (Figure 5) shows a percentage of new bone mean difference of 43.3% and
a p-value < 0.001 (95% CI: 33.6 to 52.9, heterogeneity I2 = 97.7%, P < 0.001) at 12 weeks after
the intervention.
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Figure 5. Forest plot: studies evaluating the percentage of bone formation at 12 weeks after the local
application of statins in the treatment group versus no introduction of filling material or the introduction
of polylactic acid in the control group.
Even with those encouraging results, regrettably, much value cannot be given to these
meta-analyzes, since they only include two studies that are heterogeneous.
4. Discussion
In one of the three studies i which the area f reossification was measured [9], no significant
results were obtai ed a ter the nterve ion, although in all those in which the percentage of new
bone formed was measured [8,10,16,18], a very similar parameter, all the findings were statistically
significant. The reason for no significance could be due to the concentrations of simvastatin used, since
it was the only work in which it was said that some of the animals in the intervention group suffered
neurological sequelae, so that the dose administered was perhaps too high.
In the same study [9], bone density was analyzed, and no significant increase in density was
observed at 2 months, unlike in the rest of the studies [10,13,18]. However, this increase in the density
did occur at 30 days, but then the values remained below the values of the control group over time.
That could also be correlated with the concentration of statins. Too high of a concentration may not
have beneficial effects on bone regeneration; on the contrary, it could harm the normal regeneration
process and have adverse effects, such as necrosis, the formation of granulation tissue and inflammatory
infiltration, and muscular degeneration [11].
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Three papers analyzed the osteoblasts: one in which the density was measured and the results
were statistically significant [13]; another in which the numbers of osteoblasts per area were counted
also, with statistically significant results [19]; and the last one in which the percentage of trabecular
surface covered by osteoblasts was evaluated, wherein the values were higher than in the control
group but not enough to be meaningful [17]. That lack of significance could be due to the scarcity of
the samples. Larger samples could give us results of greater value.
In all the studies that analyzed bone healing [11–15], BMP-2 [8,10,13,16], VEGF [10,13], EPCs [8,13]
and osteocalcin [10–13], statistically significant results were obtained when the intervention group
was compared with the control group. These studies showed differences in the type of simvastatin
used, doses and other substances that were part of the filling material. This seems to indicate
that a concentration of statins which is not too high to avoid the appearance of adverse effects can
be very useful in the regeneration of bone defects, independently of the other components of the
implanted substance.
It seems that the local application of statins could statistically improve some of the key parameters
in bone formation, such as BMSCs [8], osteoprotegerin [10], alkaline phosphatase enzyme [10],
RANKL [10] and osteoclasts [19], although more studies are needed to confirm the role of statins in
osteogenesis, since these values were analyzed only once.
In one of the papers, it was concluded that the improvement in angiogenesis induced by statins
favors the fracture union, after analyzing capillary density and angiogenic markers, such as eNOS and
SDF-1 [13].
Recently, three pilot studies in humans have been published using simvastatin for bone
regeneration [26–28]. In one of them [26], the healing of maxillary third molar postextraction
sockets was compared clinically and radiologically after the application of different preservation
materials: deproteinized bovine bone mineral with 10% collagen, poly(D,L-lactide-co-glycolide) with
a hydroxyapatite/β-tricalcium phosphate scaffold (PLGA/HA); poly(D,L-lactide-co-glycolide) and
hydroxyapatite/β-tricalcium phosphate with a 2% simvastatin scaffold (PLGA/HA/S); and spontaneous
healing. The results were not as expected, as there were more failures in sockets filled with PLGA/HA
scaffolds with and without simvastatin. Scaffolds with simvastatin showed better results, with less
clinical complications than scaffolds without simvastatin. The same conclusion comes from the study
by Papadimitriou et al., conducted on 14 New Zealand white rabbits, not included in this review for
not meeting criteria, when it suggests that the local application of simvastatin, combined with an
appropriate carrier, can promote new bone formation [27].
The two other pilot studies compared the use of β-tricalcium phosphate with or without
simvastatin [28], or the use of a bovine bone substitute with or without simvastatin [29], in maxillary
sinus augmentation. In the first [28], radiographic follow-up was complemented with a biopsy after 9
months. Histomorphometric results showed that the amount of newly formed bone was statistically
significantly higher in the simvastatin group. Because the patients of the intervention group showed
an intense postoperative inflammatory reaction, the authors emphasize that the dose of simvastatin
should be re-evaluated. The second pilot study [29] performed a radiographic follow-up until 9 months,
evaluating alveolar bone height, the vertical height of the grafted bone and density. The results did
not show any significant positive effect for simvastatin in maxillary sinus augmentation based on
radiographic examination. Perhaps the histological study could have shown positive results, as the
previous paper.
No other reviews evaluating the effect of local application of statins on the regeneration of
non-periodontal bone defects have been found, but a recent systematic review on the use of statins in
implantology for animal models (rats and dogs), obtained a significant increase in the osteogenesis
around the implants, in cases where the drug was administered locally, applied directly to the surface
of the implant [30]. In a similar way to the present work, the articles included in this review also
mainly used simvastatin in different concentrations, although in some cases fluvastatin was used, and
the follow-up periods ranged from 14 to 84 days.
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There are meta-analyses that refer to the use of statins as an adjunct to scaling and root planning
in humans. As two of the most recent analyses, it was concluded that the application of statins
together with mechanical periodontal treatment significantly reduces the clinical attachment level and
periodontal bone defects [31,32]. Both analyzed studies with long follow-up periods of up to 9 months,
in which the statins used were simvastatin, rosuvastatin and atorvastatin, the latter not used in any of
the studies of the present review. Although most of the studies that analyze statins used gels with
concentrations of 1.2% and 2%, some work in which the drug is administered orally exist for both cases.
As far as limitations of this review go, it should be noted that the studies are different in
terms of filler material (statin used, dose and complementary substances), the animal model and
the parameters analyzed. In addition, the samples are small and the follow-up periods are short.
Because some quantitative data are not provided in the studies, only two studies have been included
in the meta-analyses.
Even the positive results obtained in animal model, considering the scarce and incipient pilot
studies with ambiguous results, more homogeneous human studies, with larger and randomized
samples and histological evaluation, are needed.
In conclusion, the local application of statins could be a promising therapeutic strategy for the
regeneration of bone defects due to its apparent osteogenic and angiogenic effect. Further randomized
clinical trials with larger samples and histological studies are necessary to establish its effect.
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